Importantly, evaluation of paired pre-treatment and on-treatment biopsies revealed that, despite inhibition of multiple pathway targets, the degree of MAPK inhibition achieved in patients with BRAF-mutant CRC is less than that observed in patients with melanoma treated with RAF inhibitor alone.8,9. This evidence concerns the gene BRAF and colorectal carcinoma.